NEW YORK – A large-scale cancer proteomics study conducted by researchers from the University of Texas MD Anderson Cancer Center and elsewhere has found that integrating perturbed protein response signals provides mechanistic insights into drug resistance, increases the predictive power for drug sensitivity, and helps identify effective therapeutic combinations.